<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591132</url>
  </required_header>
  <id_info>
    <org_study_id>130175</org_study_id>
    <nct_id>NCT04591132</nct_id>
  </id_info>
  <brief_title>Technology-based Analysis of Movement Disorders</brief_title>
  <official_title>Technology-based Analysis of Movement Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To generate pilot data to investigate the feasibility and the potential use in&#xD;
      clinical practice of technology based objective measures of motor performances in patients&#xD;
      affected by different movement disorders. To correlate kinematics findings with demographic&#xD;
      and clinical details. Trial design and methods: Participants enrolled in prof. Bhatia's&#xD;
      movement disorders clinic, will be classifies according to the main movement disorder,&#xD;
      specifically, tremor, parkinsonism, dystonia, chorea, ataxia. In the study visit (one day&#xD;
      only), they will undergo a clinical evaluation using the appropriate clinical scales&#xD;
      (respectively, Fahn-Tolosa-Marin tremor rating scale, MDS-UPDRS Part III, Toronto Western&#xD;
      Spasmodic Torticollis Rating Scale 2, Unified Hungtington Disease Rating scale and Scale for&#xD;
      the Assessment and Rating of Ataxia) and a kinematic evaluation, using wearables and an&#xD;
      infra-red and LED markers system. Then the protocol is concluded and they will continue the&#xD;
      routine clinical follow-up&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gait metrics</measure>
    <time_frame>up to 6 weeks after enrolment</time_frame>
    <description>gait cycles measures (step length, phase duration, number of steps) practice of technology based objective measures of motor performances in patients affected by different movement disorders, to objectively evaluate the disease burden, the efficacy of therapeutic interventions and having a deeper phenotyping of motor disabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tremor peak frequence</measure>
    <time_frame>up to 6 weeks after enrolment</time_frame>
    <description>fourier analysis for peak frequence of tremor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neck ROM</measure>
    <time_frame>up to 6 weeks after enrolment</time_frame>
    <description>range of motion of the neck in x,y and z axis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bradykinesia evaluation</measure>
    <time_frame>up to 6 weeks after enrolment</time_frame>
    <description>amplitude of repeated limb movements over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation with UPDRS gait Item</measure>
    <time_frame>up to 6 weeks after enrolment</time_frame>
    <description>correlation of gait metrics with UPDRS gait score included.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>kinematic analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>kinematic analysis</intervention_name>
    <description>motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors</description>
    <arm_group_label>kinematic analysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of parkinsonism and/or dystonia and/or tremor due to:&#xD;
&#xD;
               1. idiopatic parkinson's disease&#xD;
&#xD;
               2. atypical parkinsonism&#xD;
&#xD;
               3. sporadic or inherited/genetic dystonia&#xD;
&#xD;
               4. young-onset Parkinson's disease&#xD;
&#xD;
               5. Ataxia syndrome&#xD;
&#xD;
               6. Choereic syndrome&#xD;
&#xD;
               7. Essential tremor&#xD;
&#xD;
               8. Dystonic tremor&#xD;
&#xD;
          -  18 to 80 years of age&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  able to walk unassisted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Change in pharmacological therapy in the last 3 months.&#xD;
&#xD;
          -  Participated in a clinical drug trial up to 3 months before inclusion into the present&#xD;
             study&#xD;
&#xD;
          -  Orthopaedical comorbidities affecting gait or posture.&#xD;
&#xD;
          -  Cognitive deficit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>kailash P Bhatia</last_name>
    <phone>020 3448 4229</phone>
    <email>k.bhatia@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>giulia di lazzaro</last_name>
    <phone>02034484229</phone>
    <email>giulia.dilazzaro@nhs.net</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

